GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that The New England Journal of Medicine has published results from a Phase 3 study of Epidiolex® (cannabidiol) in children with Dravet syndrome.1 Epidiolex, GW’s lead product candidate and the potential first in a new category of anti-epileptic drugs, is a liquid formulation of purified, plant-derived cannabidiol (CBD), a non-psychoactive cannabinoid, which is being studied for the treatment of a number of rare, severe pediatric-onset epilepsy disorders. In the study, Epidiolex significantly reduced monthly convulsive seizure frequency compared to placebo in highly treatment-resistant children when added to existing treatment. Treatment with Epidiolex was generally well tolerated, with a safety profile consistent with prior open label experience.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8109951-gw-pharmaceuticals-study-epidiolex/
Leading scientists have released the latest results of the large scale trials related to nuts consumption and health, particularly in myocardial infarction, stroke and cardiovascular diseases. Recent scientific studies show the benefits of regular intake of nuts, not only associated with cardiovascular health but also with renal function, diabetes, cognitive function, atherosclerosis, metabolic syndrome, inflammatory biomarkers, etc. It is important to highlight that scientific evidence demonstrates that eating nuts is not associated with a higher risk of weight gain, and even reinforce their importance as sources of key nutrients.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62432-scientifically-proven-nuts-are-not-fattening
Asuragen Inc., a leading molecular diagnostics company, today announced results from a study demonstrating that a new molecular test called Xpansion Interpreter® can improve the determination of a woman’s risk of having a child with fragile X syndrome, the most common inherited cause of intellectual disability and autism, compared to existing risk measures. The Xpansion Interpreter Test is based on a technology breakthrough that reveals both the number and position of “interrupting” DNA sequences in the fragile X gene of the mother and more accurately estimates the likelihood that her child will have fragile X syndrome. The study will be published in the April issue of the American Journal of Medical Genetics and presented today at the 2013 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting in Phoenix, AZ.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60719-asuragen-xpansion-interpreter-xi-test-data-fragile-x-syndrome-autism
Almirall, S.A. (ALM:MC) and Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced today that the European Commission has granted marketing authorization to Constella® (linaclotide 290mcg) for the symptomatic treatment of moderate to severe Irritable Bowel Syndrome with Constipation (IBS-C) in adults . This approval follows the positive recommendation received from the European Committee for Medicinal Products for Human Use (CHMP) in September.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58658-almirall
Today the International OCD Foundation (IOCDF), announced their support for children and families suffering from Sudden Onset Obsessive Compulsive Disorder. They are releasing two new PSAs created to bring awareness and engender change surrounding the disorder PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal infections) and PANS (Pediatric Acute-Onset Neuropsychiatric Syndrome).
To view Multimedia News Release, go to http://www.multivu.com/mnr/54781-ocd-foundation-pandas-psa-obsessive-compulsive-disorder
http://igetitapps.com/ i Get It offers some of the best educational apps for iPad, iPhone and iPod Touch, autism apps, and iPad apps for special needs kids. i Get It applications are designed to support language skill development and facilitate cognitive growth through building language skills. Typically developing young children and individuals with developmental delays, such as PDD-NOS, autism, down syndrome or TBI will benefit from these interactive applications. Autism apps have been recently featured on TV shows as a great way of communication for people whose condition prevents them from speaking. i Get It apps have been featured on AutismSpeaks.org, Snapps4kids.com, A4cwsn and many others. Please go to http://igetitapps.com/ to see all our apps.
Nearer Than Sky from acclaimed author T. Greenwood is a lush, evocative novel about the fascinating and frightening world of Munchausen syndrome by proxy, and into one woman’s search for healing. As she revisits her childhood, with its nightmares and lost innocence, she must reevaluate her adulthood choices, including her most precious relationships. Learn about the book here, http://bit.ly/nFTYrf Learn about this author here, http://bit.ly/oIyepZ General Fiction
Mark Saxton, MD, pediatric surgeon at Gundersen Lutheran Health System in La Crosse, Wis., is performing a minimally invasive surgery to correct pectus excavatum (sunken chest) in adults.
“Sunken chest is a birth defect characterized by a sunken sternum or breastbone,” explains Dr. Saxton. “The deformity tends to worsen until the patient is full grown and will not improve with age. It is caused by extreme growth of cartilage that connects each rib to the sternum. This causes the sternum to buckle in towards the spine.”
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/gundluth/43811/
Parents and grandparents rarely disagree about how cute their (grand)children are, but when it comes to setting up safe sleep environments for babies, the two generations don’t always concur, according to a new study conducted by Ipsos Public Affairs on behalf of HALO Innovations in time for National Baby Safety Month. The survey found that the majority of parents and grandparents agree that Sudden Infant Death Syndrome (SIDS) is their top concern in raising their children. However, grandparents are more likely than parents to place babies on their sides or stomachs to sleep, and more likely to place potentially dangerous objects in babies’ cribs, increasing their risk for SIDS and accidental suffocation.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/halosleepsacks/46013/
The truly ergonomic HandShoe Mouse has been designed to stop pinching and gripping like you do with a standard computer mouse. Gripping and Pinching is a major cause for Repetitive Strain Injury RSI) and Carpal Tunnel Syndrome.
This ergonomic mouse (the HandShoe mouse) also prevents that your fingers are hovering above the mouse buttons, another cause for RSI and capral tunnel syndrome. The HandShoe mouse has been developed by a medical university and has been tested in large organizations for almost two years.
The ergonomic HandShoe Mouse is the only mouse that fits like a glove!
Lots of people are suffering from RSI or Carpal Tunnel Syndrome due to use of a conventional computer mouse.
With the HandShoeMouse your hand is fully supported in the ideal, relaxed position.
The patented design has been developed by a medical university and has been field tested for almost two years.
This is the only ergonomic mouse that is backed by extensive research, performed by several universities.
Feel the difference!
